A complement-optimized EGFR antibody improves cytotoxic functions of polymorphonuclear cells against tumor cells

Journal of Immunology

Volumn 195, Issue 10, 2015, Pages 5077-5087

  Derer, Stefanie ^a,b   Cossham, Michael ^a   Rösner, Thies ^a   Kellner, Christian ^a   Beurskens, Frank J ^c   Schwanbeck, Ralf ^a   Lohse, Stefan ^d   Sina, Christian ^b   Peipp, Matthias ^a   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c GENMAB   (Netherlands)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ANAPHYLATOXIN; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GLUTAMIC ACID; LYSINE; MATUZUMAB; C5AR1 PROTEIN, HUMAN; CANCER ANTIBODY; COMPLEMENT COMPONENT C5A; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

AMINO ACID SUBSTITUTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER INHIBITION; CELL INTERACTION; CELL STIMULATION; CELL SURFACE; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT DEPOSITION; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MONONUCLEAR CELL; NATURAL KILLER CELL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; TUMOR CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; LEUKOCYTE; NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; COMPLEMENT C5A; HUMANS; LEUKOCYTES; NEOPLASMS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84958598311     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501458     Document Type: Article

References (54)

1. Ciardiello, F., and G. Tortora. 2008. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358: 1160-1174.
2. Zhang, W., M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H. M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al. 2007. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 25: 3712-3718.
3. Pirker, R., J. R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, F. de Marinis, W. E. Eberhardt, L. Paz-Ares, S. Störkel, et al. 2012. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13: 33-42.
4. Bardelli, A., and S. Siena. 2010. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28: 1254-1261.
5. Peipp, M., M. Dechant, and T. Valerius. 2008. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr. Opin. Immunol. 20: 436-443.
6. Di Gaetano, N., E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay. 2003. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171: 1581-1587.
7. Beurskens, F. J., M. A. Lindorfer, M. Farooqui, P. V. Beum, P. Engelberts, W. J. Mackus, P. W. Parren, A. Wiestner, and R. P. Taylor. 2012. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 188: 3532-3541.
8. Dechant, M., W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J. J. Lammerts van Beuren,W. K. Bleeker, P.W. H. I. Parren, J. G. van deWinkel, and T. Valerius. 2008. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 68: 4998-5003.
9. Rösner, T., S. Lohse, M. Peipp, T. Valerius, and S. Derer. 2014. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop. J. Immunol. 193: 1485-1495.
10. Hsu, Y. F., D. Ajona, L. Corrales, J. M. Lopez-Picazo, A. Gurpide, L. M. Montuenga, and R. Pio. 2010. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol. Cancer 9: 139-146.
11. Dienstmann, R., A. Patnaik, R. Garcia-Carbonero, A. Cervantes, M. Benavent, S. Roselló, B. B. Tops, R. S. van der Post, G. Argilés, N. J. Skartved, et al. 2015. Safety and activity of the first-in-class sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 5: 598-609.
12. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
13. Derer, S., F. J. Beurskens, T. Rösner, M. Peipp, and T. Valerius. 2014. Complement in antibody-based tumor therapy. Crit. Rev. Immunol. 34: 199-214.
14. Wang, S. Y., E. Racila, R. P. Taylor, and G. J. Weiner. 2008. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111: 1456-1463.
15. Lefebvre, M. L., S. W. Krause, M. Salcedo, and A. Nardin. 2006. Ex vivoactivated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J. Immunother. 29: 388-397.
16. Bologna, L., E. Gotti, F. Da Roit, T. Intermesoli, A. Rambaldi, M. Introna, and J. Golay. 2013. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J. Immunol. 190: 231-239.
17. Wang, S. Y., S. Veeramani, E. Racila, J. Cagley, D. C. Fritzinger, C. W. Vogel, W. St John, and G. J. Weiner. 2009. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 114: 5322-5330.
18. Pievani, A., C. Belussi, C. Klein, A. Rambaldi, J. Golay, and M. Introna. 2011. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood 117: 510-518.
19. van Meerten, T., R. S. van Rijn, S. Hol, A. Hagenbeek, and S. B. Ebeling. 2006. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin. Cancer Res. 12: 4027-4035.
20. Duncan, A. R., and G. Winter. 1988. The binding site for C1q on IgG. Nature 332: 738-740.
21. Painter, R. H. 1984. The C1q receptor site on human immunoglobulin G. Can. J. Biochem. Cell Biol. 62: 418-425.
22. Gaboriaud, C., J. Juanhuix, A. Gruez, M. Lacroix, C. Darnault, D. Pignol, D. Verger, J. C. Fontecilla-Camps, and G. J. Arlaud. 2003. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J. Biol. Chem. 278: 46974-46982.
23. Idusogie, E. E., L. G. Presta, H. Gazzano-Santoro, K. Totpal, P. Y. Wong, M. Ultsch, Y. G. Meng, and M. G. Mulkerrin. 2000. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164: 4178-4184.
24. Diebolder, C. A., F. J. Beurskens, R. N. de Jong, R. I. Koning, K. Strumane, M. A. Lindorfer, M. Voorhorst, D. Ugurlar, S. Rosati, A. J. R. Heck, et al. 2014. Complement is activated by IgG hexamers assembled at the cell surface. Science 343: 1260-1263.
25. Idusogie, E. E., P. Y. Wong, L. G. Presta, H. Gazzano-Santoro, K. Totpal, M. Ultsch, and M. G. Mulkerrin. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166: 2571-2575.
26. Peipp, M., J. J. Lammerts van Bueren, T. Schneider-Merck, W. W. Bleeker, M. Dechant, T. Beyer, R. Repp, P. H. van Berkel, T. Vink, J. G. van de Winkel, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
27. Repp, R., C. Kellner, A. Muskulus, M. Staudinger, S. M. Nodehi, P. Glorius, D. Akramiene, M. Dechant, G. H. Fey, P. H. van Berkel, et al. 2011. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J. Immunol. Methods 373: 67-78.
28. Moore, G. L., H. Chen, S. Karki, and G. A. Lazar. 2010. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2: 181-189.
29. Ehrengruber, M. U., T. Geiser, and D. A. Deranleau. 1994. Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett. 346: 181-184.
30. Derer, S., P. Glorius, M. Schlaeth, S. Lohse, K. Klausz, U. Muchhal, J. R. Desjarlais, A. Humpe, T. Valerius, and M. Peipp. 2014. Increasing FcgRIIa affinity of an FcgRIII-optimized anti-EGFR antibody restores neutrophilmediated cytotoxicity. MAbs 6: 409-421.
31. van Spriel, A. B., J. H. Leusen, M. van Egmond, H. B. Dijkman, K. J. Assmann, T. N. Mayadas, and J. G. van de Winkel. 2001. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 97: 2478-2486.
32. Diamond, M. S., and T. A. Springer. 1993. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J. Cell Biol. 120: 545-556.
33. Brekke, O. L., D. Christiansen, H. Fure, M. Fung, and T. E. Mollnes. 2007. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coliinduced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J. Leukoc. Biol. 81: 1404-1413.
34. Foreman, K. E., M. M. Glovsky, R. L. Warner, S. J. Horvath, and P. A. Ward. 1996. Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation 20: 1-9.
35. Min, X., C. Liu, Y. Wei, N. Wang, G. Yuan, D. Liu, Z. Li, W. Zhou, and K. Li. 2014. Expression and regulation of complement receptors by human natural killer cells. Immunobiology 219: 671-679.
36. Charriaut, C., A. Senik, J. P. Kolb, M. Barel, and R. Frade. 1982. Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment. Proc. Natl. Acad. Sci. USA 79: 6003-6007.
37. Sehgal, G., K. Zhang, R. F. Todd, III, L. A. Boxer, and H. R. Petty. 1993. Lectinlike inhibition of immune complex receptor-mediated stimulation of neutrophils. Effects on cytosolic calcium release and superoxide production. J. Immunol. 150: 4571-4580.
38. Zhou, M. J., and E. J. Brown. 1994. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J. Cell Biol. 125: 1407-1416.
39. Zhou, M., and E. J. Brown. 1993. Leukocyte response integrin and integrinassociated protein act as a signal transduction unit in generation of a phagocyte respiratory burst. J. Exp. Med. 178: 1165-1174.
40. Ehlenberger, A. G., and V. Nussenzweig. 1977. The role of membrane receptors for C3b and C3d in phagocytosis. J. Exp. Med. 145: 357-371.
41. Price, P. J., Z. Bánki, A. Scheideler, H. Stoiber, A. Verschoor, G. Sutter, and M. H. Lehmann. 2015. Complement component C5 recruits neutrophils in the absence of C3 during respiratory infection with modified vaccinia virus Ankara. J. Immunol. 194: 1164-1168.
42. Hünniger, K., K. Bieber, R. Martin, T. Lehnert, M. T. Figge, J. Löffler, R. F. Guo, N. C. Riedemann, and O. Kurzai. 2015. A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a. J. Immunol. 194: 1199-1210.
43. Gunn, L., C. Ding, M. Liu, Y. Ma, C. Qi, Y. Cai, X. Hu, D. Aggarwal, H. G. Zhang, and J. Yan. 2012. Opposing roles for complement component C5a in tumor progression and the tumor microenvironment. J. Immunol. 189: 2985-2994.
44. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.
45. Montresor, A., L. Toffali, G. Constantin, and C. Laudanna. 2012. Chemokines and the signaling modules regulating integrin affinity. Front. Immunol. 3: 127-136.
46. Mócsai, A., C. L. Abram, Z. Jakus, Y. Hu, L. L. Lanier, and C. A. Lowell. 2006. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat. Immunol. 7: 1326-1333.
47. Shushakova, N., J. Skokowa, J. Schulman, U. Baumann, J. Zwirner, R. E. Schmidt, and J. E. Gessner. 2002. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 110: 1823-1830.
48. Godau, J., T. Heller, H. Hawlisch, M. Trappe, E. Howells, J. Best, J. Zwirner, J. S. Verbeek, P. M. Hogarth, C. Gerard, et al. 2004. C5a initiates the inflammatory cascade in immune complex peritonitis. J. Immunol. 173: 3437-3445.
49. Kumar, V., S. R. Ali, S. Konrad, J. Zwirner, J. S. Verbeek, R. E. Schmidt, and J. E. Gessner. 2006. Cell-derived anaphylatoxins as key mediators of antibodydependent type II autoimmunity in mice. J. Clin. Invest. 116: 512-520.
50. Hong, F., R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross. 2003. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 63: 9023-9031.
51. Allendorf, D. J., J. Yan, G. D. Ross, R. D. Hansen, J. T. Baran, K. Subbarao, L. Wang, and B. Haribabu. 2005. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J. Immunol. 174: 7050-7056.
52. Li, B., D. J. Allendorf, R. Hansen, J. Marroquin, D. E. Cramer, C. L. Harris, and J. Yan. 2007. Combined yeast beta-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decayaccelerating factor CD55. Cancer Res. 67: 7421-7430.
53. Zhu, E. F., S. A. Gai, C. F. Opel, B. H. Kwan, R. Surana, M. C. Mihm, M. J. Kauke, K. D. Moynihan, A. Angelini, R. T. Williams, et al. 2015. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27: 489-501.
54. Clark, M. R. 1997. IgG effector mechanisms. Chem. Immunol. 65: 88-110.